Psoriatic arthritis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Psoriatic arthritis}} {{CMG}}; {{AE}} {{CK}} ==Overview== === Prevention === * There are no established preventive measures for Psoriatic arthritis (patient inf...") |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
== | There are no established secondary preventive measures for psoriatic arthritis. | ||
* There are no established preventive measures for | == Secondary prevention === | ||
* Patients are monitored regularly for [[disease]] activity, [[:Category:Drugs|drug]] efficacy, [[Adverse effect (medicine)|adverse effects]] and associated [[Comorbidity|comorbid conditions]]. | * There are no established secondary preventive measures for psoriatic arthritis. | ||
* Patients are monitored regularly for [[disease]] activity, [[:Category:Drugs|drug]] efficacy, [[Adverse effect (medicine)|adverse effects]] and associated [[Comorbidity|comorbid conditions]].<ref name="pmid14730596">{{cite journal |vauthors=Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W |title=Assessment of patients with psoriatic arthritis: a review of currently available measures |journal=Arthritis Rheum. |volume=50 |issue=1 |pages=24–35 |date=January 2004 |pmid=14730596 |doi=10.1002/art.11417 |url=}}</ref> | |||
==References== | ==References== | ||
Revision as of 18:32, 14 May 2018
|
Psoriatic arthritis Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Psoriatic arthritis secondary prevention On the Web | |
|
American Roentgen Ray Society Images of Psoriatic arthritis secondary prevention | |
|
Risk calculators and risk factors for Psoriatic arthritis secondary prevention | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [2]
Overview
There are no established secondary preventive measures for psoriatic arthritis.
Secondary prevention =
- There are no established secondary preventive measures for psoriatic arthritis.
- Patients are monitored regularly for disease activity, drug efficacy, adverse effects and associated comorbid conditions.[1]
References
- ↑ Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W (January 2004). "Assessment of patients with psoriatic arthritis: a review of currently available measures". Arthritis Rheum. 50 (1): 24–35. doi:10.1002/art.11417. PMID 14730596.